http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2418592-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b47e3e05f88d9cffadea80bfde670a70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b0c4ac671ef34cc04cf952e2442fca3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b5295baf4c1e78545f6d5ee0b56d2fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64f8b053496dee4df666fbeb6b9ec979 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate | 2010-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c977c85d90e1af9317f381dae106b25f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41e021eedef1ccd546495b614b8ff7c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_714197c43f6ca5ffb22ad7ab1a576264 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_623642ab5418c1400447640c85cbb62b |
| publicationDate | 2011-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2418592-C1 |
| titleOfInvention | Method of treating arterial hypertension |
| abstract | FIELD: medicine. ^ SUBSTANCE: invention relates to field of medicine, namely, to therapy and cardiology, and deals with treatment of arterial hypertension. For this purpose into complex of conventional therapy additionally introduced is prostaglandin E2 in form of 0.0008% solution. Prostaglandin is introduced intravenously, starting with rate 50-100 ng/kg/min, increasing rate of introduction each 10 minutes on 20-40 ng/kg/min, bringing rate to 150-300 ng/kg/min during 40-60, minutes. Altogether there are three introductions per a course with 1-2 day intervals between them. ^ EFFECT: additional introduction of prostaglandin E2 in elaborated doses and regimen ensures efficient normalisation of arterial pressure during long term due to enhance of excretion of prostaglandins by kidneys, expressed vasodilation of vessels of kidneys, heart and brain, as well as normalisation of functional activity of platelets. ^ 6 ex |
| priorityDate | 2010-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 175.